[PRESS RELEASE] – EDMONTON, Alberta, Aug. 19, 2026 – Aurora Cannabis Inc., the Canadian-based leading global medical cannabis company, has acquired Internode Pharma Limited, a licensed importer and wholesaler, and HAP Pharma Limited, a licensed pharmacy (the "companies").
"The acquisition of Internode Pharma Limited and HAP Pharma Limited mark a further strategic milestone for Aurora as we continue to purposefully invest in expanding our leadership in the rapidly growing international medical cannabis market,” Aurora Executive Chairman and CEO Miguel Martin said. “We believe that this transaction will allow us to fully leverage our operational, commercial and regulatory expertise to expand our market share, while also supporting a consistent and reliable supply of high-quality medical cannabis products to U.K. patients.
"Given the growing patient demand, strong acceptance of our products and increasingly prescriptive regulatory standards, the U.K. represents an exciting opportunity for us, and acquiring these companies provides Aurora with greater agility to more reliably serve U.K. patients.”
Strategic Rationale
- The U.K. is one of the largest European medical cannabis markets, representing a population of approximately 70 million people.
- The companies operate a licensed import and distribution facility and a virtual pharmacy in Birmingham, United Kingdom, providing Aurora with direct ownership and control of the supply chain from cultivation through to delivery to patients.
- Aurora intends to leverage its commercial, regulatory and operational expertise to streamline distribution and drive market share gains in the rapidly growing U.K. medical cannabis market.
- This transaction is expected to be accretive to adjusted EBITDA contributions in future quarters due to operational efficiencies and reduced reliance on third parties to distribute Aurora's products to patients.
- Aurora intends to evaluate further investment opportunities to expand distribution capacity in the U.K. to support increasing patient demand.
Transaction Details
Aurora, through a wholly-owned subsidiary, indirectly purchased 100% of the shares of Internode Pharma Limited and HAP Pharma Limited. As consideration on closing, Aurora paid the selling shareholders GBP 2.1 million in cash, contingent on the satisfaction of certain conditions post-closing.
